OPKO Health (OPK) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
OPKO Announces Second Quarter Operating and Financial Results
August 5, 2015 4:00 PM EDTAnnounced the Acquisition of Bio-Reference Laboratories; Closing Anticipated by the End of August Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer RayaldeeTM New Drug Application (NDA) Submission Accepted by FDA; Expected PDUFA date of March 29, 2016 Completed the Enrollment in hGH-CTP Phase 3 Trial in Growth Hormone Deficient Adults New Pre-Clinical Data Supporting Subcutaneous Administration for Long Acting Factor VIIa-CTP for Hemophilia; Phase 2a Clinical Trial Expected to Commence in Q3 2015... More
